This case focuses on the 2001 negotiations between Mytex pharmaceuticals and the U.S. Food and Drug Administration (FDA). Outcome of the negotiations will determine the new label for the blockbuster drug for arthritis Mytex, Flaxil. Negotiations rather qualitative and different from the typical price negotiations with which students are familiar. However, at stake was $ 500 million in sales Flaxil and security of millions of patients. Attached is an epilogue to the case. "Hide
by Gregory Barron Source: Harvard Business School 4 pages. Publication Date: August 24, 2008. Prod. #: 909003-PDF-ENG
Related Case Solutions & Analyses:
Sony and the JK Wedding Dance
Radiohead: Music at Your Own Price (B)
Radiohead: Music at Your Own Price (A)
Learning to Manage with Data in Duval County Public Schools: Lake Shore Middle School (A)
Apollo Hospitals–First-World Health Care at Emerging-Market Prices
Driving Change at Seagate
Valuing a Cross-Border LBO: Bidding on the Yell Group
Note on Crude Oil and Crude Oil Derivatives Markets
A Descriptive study of Preventionof Incarceration of African American Males through non-profit options
Project Management
